Holen Sie sich die Stockscreener-App
2.25
2.60%
-0.06
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - Defense World
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan
Dogwood Therapeutics Q4 net loss narrows on lower expenses - TradingView
Dogwood Therapeutics extends cash runway as pain drug trial advances - Stock Titan
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7%Time to Buy? - MarketBeat
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal - The Globe and Mail
Dogwood Therapeutics, Inc. 8-K SEC Filing March 11, 2026: Company Information, Stock, and Key Details - Minichart
Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - The Manila Times
Sentiment Watch: What is the long term forecast for Dogwood Therapeutics Inc stockTrend Reversal & Accurate Buy Signal Alerts - baoquankhu1.vn
Maxim Group Sticks to Its Buy Rating for Dogwood Therapeutics (DWTX) - The Globe and Mail
Dogwood Therapeutics (DWTX) CMO receives grant of 82,500 stock options - Stock Titan
Dogwood Therapeutics (DWTX) awards CFO Angela Walsh 82,500 stock options - Stock Titan
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Does Dogwood Therapeutics Inc stock benefit from AI growthJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
DWTXDogwood Therapeutics Latest Stock News & Market Updates - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Earns Buy Rating from HC Wainwright - Defense World
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Praxis Precision Medicines (PRAX) and Dogwood Therapeutics (DWTX) - The Globe and Mail
Is Dogwood Therapeutics Inc. stock showing strong momentumMarket Volume Report & Growth Oriented Trading Recommendations - mfd.ru
What’s the MACD signal for Dogwood Therapeutics Inc.Trade Entry Summary & Reliable Entry Point Trade Alerts - mfd.ru
Market Wrap: How cyclical is Dogwood Therapeutics Incs revenue streamDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Pullback Watch: Whats the MACD signal for Dogwood Therapeutics Inc2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
What’s the analyst consensus on Dogwood Therapeutics Inc.July 2025 Gainers & Reliable Price Action Trade Plans - mfd.ru
Will Dogwood Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - mfd.ru
Will Dogwood Therapeutics Inc. benefit from geopolitical trendsEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
How is Dogwood Therapeutics Inc. managing supply chain issuesQuarterly Portfolio Review & Low Risk Entry Point Guides - mfd.ru
What is the PEG ratio of Dogwood Therapeutics Inc.Weekly Profit Analysis & Accurate Buy Signal Notifications - mfd.ru
Why Dogwood Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 Snapshot & Technical Confirmation Trade Alerts - mfd.ru
DWTX: Financing Secures Funding Through Phase 2b Data Readout - Smartkarma
Institution Moves: Will Dogwood Therapeutics Inc. benefit from geopolitical trends2025 Macro Impact & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - markets.businessinsider.com
Cancer pain drug Halneuron shows early promise as major trial hits halfway - Stock Titan
What is Dogwood Therapeutics Inc.’s book value per share2025 Earnings Surprises & Low Risk Profit Maximizing Plans - mfd.ru
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Analysis Recap: Is AAON Inc impacted by rising ratesQuarterly Profit Review & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Price Action: What is the PEG ratio of Dogwood Therapeutics IncDip Buying & Stepwise Trade Signal Guides - baoquankhu1.vn
Dogwood Therapeutics outlines 2026 plans for pain pipeline - The Globe and Mail
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):